Equity Raising Overview - Silex is undertaking an equity raising of up to $130 million through a placement to eligible investors[11] - A share purchase plan (SPP) to eligible shareholders in Australia and New Zealand aims to raise up to $15 million[11] - The placement price is fixed at $3.90 per share, representing a 15.8% discount to the last close of $4.63 per share[42] and a 10.5% discount to the 5-day VWAP of $4.36 per share[42] - SPP shares will be issued at the lower of the placement price and a 2% discount to the 5-day VWAP up to the SPP closing date[42] Use of Proceeds - The proceeds from the offer, along with existing cash of approximately $69.6 million, will primarily support GLE's commercialization of the SILEX uranium enrichment technology in the US[41, 42] - Funds will also be used to pursue Silex's additional isotope production opportunities and strengthen the company's balance sheet[41, 42] - Silex expects to be fully funded through to the end of FY2028 following the placement[42] GLE Commercialization and Opportunities - GLE aims for commercial deployment of the SILEX uranium enrichment technology by 2030[40] - GLE's strategy includes potential production of UF6, LEU/LEU+, and HALEU at the Paducah Laser Enrichment Facility (PLEF)[41] - GLE has exclusive access to valuable uranium tails inventories from the US DOE, potentially producing up to 5 million lbs p a of natural grade uranium (as UF6) for up to 30 years[41, 74, 85]